Cover Image
市場調查報告書

類澱粉蛋白沉積症:開發中產品分析

Amyloidosis - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 192465
出版日期 內容資訊 英文 152 Pages
訂單完成後即時交付
價格
Back to Top
類澱粉蛋白沉積症:開發中產品分析 Amyloidosis - Pipeline Review, H2 2016
出版日期: 2016年07月30日 內容資訊: 英文 152 Pages
簡介

以類澱粉蛋白沉積症知名的疾病群,是由於Amyloid蛋白質在體內組織異常積蓄所造成。由於會影響到內臟形狀及功能,甚至也可能最後造成臟器功能衰竭。因素有被稱為L鎖的異常蛋白質錯誤折疊,持續下去後積蓄於體內。也可能是透析結果造成。其常見的症狀有倦怠感、胸痛、腫脹、呼吸障礙等。治療方法包含有移植、給藥(利尿劑、化療藥)等。

本報告提供類澱粉蛋白沉積症的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢等相關的系統性資訊。

目錄

簡介

類澱粉蛋白沉積症概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

調查中的治療藥:大學/研究機關別

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

開發中的產品:各企業

調查中的產品:大學/研究機關別

開發治療藥的企業

  • Alnylam Pharmaceuticals, Inc.
  • Arcturus Therapeutics, Inc
  • Bellus Health Inc.
  • Bsim2
  • Celgene Corporation
  • GlaxoSmithKline Plc
  • Isis Pharmaceuticals, Inc.
  • Millennium Pharmaceuticals, Inc.
  • Onyx Pharmaceuticals, Inc.
  • Pfizer Inc.
  • ProteoTech, Inc.
  • Prothena Corporation Plc
  • SOM Innovation Biotech SL

治療藥的評估

  • 單獨療法的情況
  • 聯合治療的情況
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • ALN-TTRsc02
  • Antisense RNAi Oligonucleotides to Inhibit Amyloid Precursor Protein for Amyloidosis
  • carfilzomib
  • CLR-01
  • eprodisate disodium
  • GSK-2315698 + GSK-2398852
  • GSK-2398852
  • ixazomib citrate
  • LUNAR-101
  • LUNAR-102
  • Monoclonal Antibody for Amyloidosis
  • Monoclonal Antibody to Inhibit ATTR for Familial Amyloid Polyneuropathy
  • NEOD-001
  • NPT-005
  • patisiran
  • pomalidomide
  • PTI-110
  • revusiran
  • Small Molecules for AL Amyloidosis
  • Small Molecules to Inhibit Transthyretin for Familial Amyloid Polyneuropathy
  • Small Molecules to Inhibit Transthyretin Related Amyloid Protein for Familial Amyloidotic Cardiomyopathy
  • Small Molecules to Inhibit Transthyretin Related Amyloid Protein for Familial Amyloidotic Polyneuropathy
  • tafamidis meglumine
  • tolcapone

開發中產品的最新趨勢

暫停的計劃

開發中止的產品

產品開發的里程碑

  • 最新消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8315IDB

Summary

Global Markets Direct's, 'Amyloidosis - Pipeline Review, H2 2016', provides an overview of the Amyloidosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Amyloidosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Amyloidosis and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Amyloidosis
  • The report reviews pipeline therapeutics for Amyloidosis by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Amyloidosis therapeutics and enlists all their major and minor projects
  • The report assesses Amyloidosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Amyloidosis

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Amyloidosis
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Amyloidosis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Amyloidosis Overview
  • Therapeutics Development
    • Pipeline Products for Amyloidosis - Overview
    • Pipeline Products for Amyloidosis - Comparative Analysis
  • Amyloidosis - Therapeutics under Development by Companies
  • Amyloidosis - Therapeutics under Investigation by Universities/Institutes
  • Amyloidosis - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Amyloidosis - Products under Development by Companies
  • Amyloidosis - Products under Investigation by Universities/Institutes
  • Amyloidosis - Companies Involved in Therapeutics Development
    • Alnylam Pharmaceuticals, Inc.
    • Amgen Inc.
    • Arcturus Therapeutics, Inc.
    • BELLUS Health Inc.
    • Bsim2
    • Celgene Corporation
    • GlaxoSmithKline Plc
    • Ionis Pharmaceuticals, Inc.
    • Johnson & Johnson
    • Neurimmune Holding AG
    • NeuroPhage Pharmaceuticals, Inc.
    • Oncopeptides AB
    • Pfizer Inc.
    • Prothena Corporation Plc
    • Regeneron Pharmaceuticals, Inc.
    • SOM Innovation Biotech SL
    • Takeda Pharmaceutical Company Limited
  • Amyloidosis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • ALN-ANG - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ALN-TTRsc02 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Antisense RNAi Oligonucleotides to Inhibit Amyloid Precursor Protein for Amyloidosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • carfilzomib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CLR-01 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • daratumumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • doxycycline hyclate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EDE-1307 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GSK-2315698 + GSK-2398852 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GSK-3039294 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • inotersen sodium - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ixazomib citrate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LUNAR-TTR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Melflufen - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody for Amyloidosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit ATTR for Familial Amyloid Polyneuropathy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Target CD66b for Blood Cancer and Metabolic Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NEOD-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NI-301 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NPT-005 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Oligonucleotides to Inhibit Transthyretin for Amyloidosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • patisiran - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pomalidomide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PRX-004 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • revusiran - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for AL Amyloidosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Transthyretin for Familial Amyloid Polyneuropathy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Transthyretin Related Amyloid Protein for Familial Amyloidotic Cardiomyopathy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Transthyretin Related Amyloid Protein for Familial Amyloidotic Polyneuropathy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tafamidis meglumine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tolcapone - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Amyloidosis - Dormant Projects
  • Amyloidosis - Product Development Milestones
    • Featured News & Press Releases
      • Jul 07, 2016: Ionis Pharmaceuticals Reports Positive Clinical Data on IONIS-TTR Rx at the XV International Symposium on Amyloidosis
      • Jul 05, 2016: Prothena Presents New Data from Phase 1/2 Study of NEOD001 Demonstrating Improvements in Three Organ Systems in Previously-Treated Patients with AL Amyloidosis
      • Jul 01, 2016: Alnylam Reports New Results on patisiran at the XV International Symposium on Amyloidosis
      • Jul 01, 2016: Alnylam To Present New Results on Revusiran at the XV International Symposium on Amyloidosis
      • Jun 27, 2016: Alnylam to Report New Patisiran Results at the XV International Symposium on Amyloidosis
      • Jun 27, 2016: Alnylam to Present New Revusiran Results at the XV International Symposium on Amyloidosis
      • Jun 21, 2016: Prothena to Present at 15th International Symposium on Amyloidosis Showcasing Broad Commitment to Advancing New Therapies for Systemic Amyloidoses
      • Jun 09, 2016: Alnylam Initiates Phase 1 Clinical Trial for ALN-TTRsc02, an Investigational RNAi Therapeutic for the Treatment of TTR-Mediated Amyloidosis
      • May 26, 2016: Ionis Pharmaceuticals Provides Update on IONIS-TTR Rx Program
      • May 23, 2016: Prothena to Present Wide Range of Studies on Amyloidosis, Including New Clinical Data on NEOD001, at International Symposium on Amyloidosis
      • Apr 20, 2016: Alnylam Reports Complete 18-Month Data from Ongoing Phase 2 Open-Label Extension Study of Patisiran, an Investigational RNAi Therapeutic Targeting Transthyretin for the Treatment of Hereditary ATTR Amyloidosis with Polyneuropathy (hATTR-PN)
      • Apr 07, 2016: Ionis Pharmaceuticals Provides Update on IONIS-TTRRX Program
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Amyloidosis, H2 2016
  • Number of Products under Development for Amyloidosis - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Amyloidosis - Pipeline by Alnylam Pharmaceuticals, Inc., H2 2016
  • Amyloidosis - Pipeline by Amgen Inc., H2 2016
  • Amyloidosis - Pipeline by Arcturus Therapeutics, Inc., H2 2016
  • Amyloidosis - Pipeline by BELLUS Health Inc., H2 2016
  • Amyloidosis - Pipeline by Bsim2, H2 2016
  • Amyloidosis - Pipeline by Celgene Corporation, H2 2016
  • Amyloidosis - Pipeline by GlaxoSmithKline Plc, H2 2016
  • Amyloidosis - Pipeline by Ionis Pharmaceuticals, Inc., H2 2016
  • Amyloidosis - Pipeline by Johnson & Johnson, H2 2016
  • Amyloidosis - Pipeline by Neurimmune Holding AG, H2 2016
  • Amyloidosis - Pipeline by NeuroPhage Pharmaceuticals, Inc., H2 2016
  • Amyloidosis - Pipeline by Oncopeptides AB, H2 2016
  • Amyloidosis - Pipeline by Pfizer Inc., H2 2016
  • Amyloidosis - Pipeline by Prothena Corporation Plc, H2 2016
  • Amyloidosis - Pipeline by Regeneron Pharmaceuticals, Inc., H2 2016
  • Amyloidosis - Pipeline by SOM Innovation Biotech SL, H2 2016
  • Amyloidosis - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Amyloidosis - Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for Amyloidosis, H2 2016
  • Number of Products under Development for Amyloidosis - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top